Tom Ferguson

2.0k total citations
20 papers, 161 citations indexed

About

Tom Ferguson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tom Ferguson has authored 20 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Tom Ferguson's work include Renal cell carcinoma treatment (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Tom Ferguson is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Tom Ferguson collaborates with scholars based in Australia, United States and United Kingdom. Tom Ferguson's co-authors include Andrew Redfern, Martin Gore, Ian D. Davis, Stefan N. Symeonides, Jae‐Lyun Lee, Maggie James, Marine Gross‐Goupil, Carla de Boer, Lisa Pickering and Se Hoon Park and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and BMJ Open.

In The Last Decade

Tom Ferguson

18 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Ferguson Australia 7 73 64 49 46 31 20 161
Lisa M.C. van Hoogstraten Netherlands 6 60 0.8× 36 0.6× 59 1.2× 138 3.0× 27 0.9× 14 224
Silvia Chiellino Italy 7 102 1.4× 61 1.0× 61 1.2× 27 0.6× 23 0.7× 17 205
Qingya Yang China 8 24 0.3× 66 1.0× 58 1.2× 22 0.5× 31 1.0× 20 151
Damien Vansteene France 8 106 1.5× 69 1.1× 29 0.6× 43 0.9× 10 0.3× 25 202
Dilyara Kaidarova Kazakhstan 8 92 1.3× 37 0.6× 43 0.9× 18 0.4× 40 1.3× 61 211
Stephan Spahn Germany 6 57 0.8× 59 0.9× 47 1.0× 15 0.3× 14 0.5× 15 160
Guy Monceaux France 7 174 2.4× 71 1.1× 77 1.6× 109 2.4× 34 1.1× 7 341
Dennis Yiannakis United Kingdom 8 77 1.1× 38 0.6× 49 1.0× 19 0.4× 26 0.8× 16 208
Lindsay F. Petersen United States 7 73 1.0× 26 0.4× 46 0.9× 34 0.7× 23 0.7× 17 163
Shen-Chih Chang United States 7 59 0.8× 17 0.3× 51 1.0× 24 0.5× 27 0.9× 7 200

Countries citing papers authored by Tom Ferguson

Since Specialization
Citations

This map shows the geographic impact of Tom Ferguson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Ferguson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Ferguson more than expected).

Fields of papers citing papers by Tom Ferguson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Ferguson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Ferguson. The network helps show where Tom Ferguson may publish in the future.

Co-authorship network of co-authors of Tom Ferguson

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Ferguson. A scholar is included among the top collaborators of Tom Ferguson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Ferguson. Tom Ferguson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haas, Naomi B., Thomas Powles, Piotr Tomczak, et al.. (2025). Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(16_suppl). 4514–4514. 1 indexed citations
2.
Choueiri, Toni K., Piotr Tomczak, Se Hoon Park, et al.. (2023). Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.. Journal of Clinical Oncology. 41(6_suppl). 679–679. 3 indexed citations
3.
Viswambaram, Pravin, Elizabeth Liow, Nat Lenzo, et al.. (2022). 89 Zirconium-labelled girentuximab ( 89 Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma. BMJ Open. 12(4). e060478–e060478. 10 indexed citations
4.
Choueiri, Toni K., Piotr Tomczak, Se Hoon Park, et al.. (2022). Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.. Journal of Clinical Oncology. 40(6_suppl). 290–290. 20 indexed citations
5.
Kichenadasse, Ganessan, Carole A. Harris, Howard Gurney, et al.. (2022). Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4537–4537. 4 indexed citations
6.
Hayne, Dickon, Pravin Viswambaram, Elizabeth Liow, et al.. (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule.. Journal of Clinical Oncology. 40(6_suppl). 483–483. 2 indexed citations
7.
Choueiri, Toni K., Piotr Tomczak, Se Hoon Park, et al.. (2021). Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.. Journal of Clinical Oncology. 39(18_suppl). LBA5–LBA5. 26 indexed citations
8.
Viswambaram, Pravin, Elizabeth Liow, Andrew Redfern, et al.. (2021). Sub-urothelial durvalumab injection-1 (SUBDUE-1): A novel approach to immunotherapy for bladder cancer.. Journal of Clinical Oncology. 39(6_suppl). TPS503–TPS503. 3 indexed citations
9.
Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2021). UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.. Journal of Clinical Oncology. 39(6_suppl). 325–325. 2 indexed citations
10.
Gedye, Craig, Abhishek Joshi, Alison Yan Zhang, et al.. (2021). Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).. Journal of Clinical Oncology. 39(6_suppl). TPS367–TPS367. 1 indexed citations
11.
12.
13.
14.
Ferguson, Tom, et al.. (2013). Deep Throttle Turbopump Technology Design Concepts.
15.
Larkin, James, Tom Ferguson, Lisa Pickering, et al.. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. British Journal of Cancer. 103(8). 1149–1153. 33 indexed citations
16.
Ferguson, Tom & Martin Gore. (2010). Which patients with renal cancer may benefit from sunitinib therapy?. Therapeutic Advances in Medical Oncology. 2(2). 69–74. 2 indexed citations
17.
Ferguson, Tom & Anna K. Nowak. (2007). HER-2 and response to paclitaxel in node positive breast cancer. UWA Profiles and Research Repository (University of Western Australia). 3 indexed citations
18.
Renné, D., Peter Lilienthal, Paul Gilman, et al.. (2006). A strategic approach for promoting access to clean energy development. 1 indexed citations
19.
Ferguson, Tom, et al.. (1988). The no-nag, no-guilt, do-it-your-own-way guide to quitting smoking. Medical Entomology and Zoology. 4 indexed citations
20.
Ferguson, Tom, et al.. (1974). High phytic acid in Iranian breads. Journal of the American Dietetic Association. 65(6). 651–653. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa M.C. van Hoogstraten Breakdown of academic impact, for papers by Silvia Chiellino Breakdown of academic impact, for papers by Qingya Yang Breakdown of academic impact, for papers by Damien Vansteene Breakdown of academic impact, for papers by Dilyara Kaidarova Breakdown of academic impact, for papers by Stephan Spahn Breakdown of academic impact, for papers by Guy Monceaux Breakdown of academic impact, for papers by Dennis Yiannakis Breakdown of academic impact, for papers by Lindsay F. Petersen Breakdown of academic impact, for papers by Shen-Chih Chang
Rankless by CCL
2026